A federal panel has cited a drug manufacturer for overcharging on medicine for multiple sclerosis patients. The Patented Medicine Prices Review Board complained of a 20% price hike over seven years: “What do you know?”.
This content is for Blacklock’s Reporter members only. Please login to view this content. (Register here.)
